L&L Biopharma has multiple Sbody-based products in different development stages. Two core assets, LB1410 and LB4330, had obtained IND approvals in China and the US and have completed phase I dose escalation trials in China. LB1410 is a potential FIC PD-1/TIM-3 bispecific antibody developed for patients with PD-1/PD-L1 blockade resistant/refractory cancers. LB4330, is a pioneering immunotherapy product for patients with pancreatic and gastric cancers. 

Founded in 2015, L&L Biopharmaceutical Co., Ltd., Shanghai (L&L Biopharma) is a high-tech company specializing in the research and development of innovative biopharmaceuticals, with a focus on the bi-/multi-specific antibodies for tumor immunotherapy. L&L Biopharma has established state-of-the-art bi-/multi-specific antibody technology platforms, including hybridoma technology platform, computer-aided humanization technology platform, cell line engineering platform, and a proprietary core platform - Sequence-Specific IgG-like Bispecific Antibody (SBody) platform. The company is dedicated to addressing the clinical needs of cancer patients with primary or acquired resistance to anti-PD-1/PD-L1 therapies.